Integrating Electroporation Technology & DNA Vaccine Platforms
HONG KONG SAR -
Media OutReach - 20 September 2022 -
Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, announced today the acquisition of 92.6% of Shanghai Teresa Healthcare, the pioneer of electroporation technology and device in China.